SCHEMBL14099264

SCHEMBL14099264

CC(C)N(C)c1nccs1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN3A Q9NY46 1/20 0.42
FFAR2 O15552 1/20 0.41
HTR7 P34969 1/20 0.40
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
ALDH1A1 P00352 2/20 0.36
TSHR P16473 1/20 0.36
NOS1 P29475 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HRH1 P35367 5/20 0.35
CYP2D6 P10635 4/20 0.35
KCNH2 Q12809 4/20 0.35
CHRM1 P11229 2/20 0.35
FBP1 P09467 2/20 0.33
PDK1 Q15118 1/20 0.33
PPARG P37231 1/20 0.32
NR3C1 P04150 1/20 0.32
ADORA3 P0DMS8 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8716232 0.83 FFAR2 (0.42) SCN1ASCN2ASCN3AFFAR2HTR7
SCHEMBL19997269 0.77 FFAR2 (0.37) SCN1ASCN2ASCN3AFFAR2HTR7
SCHEMBL1903243 0.77
SCHEMBL11952511 0.75 FFAR2 (0.40) SCN1ASCN2ASCN3AFFAR2HTR7
Hydrochloric Acid SCHEMBL17080155 0.75
SCHEMBL13844015 0.74 FFAR2 (0.35) SCN1ASCN2ASCN3AFFAR2HTR7
SCHEMBL9790850 0.74 FDPS (0.45) SCN1ASCN2ASCN3AFFAR2HTR7
SCHEMBL18225231 0.73
SCHEMBL2220312 0.73
SCHEMBL9687591 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10588894-B2 Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease SHY Therapeutics LLC (US) 2020-03-17 US disclosed
US-20190022074-A1 COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY Therapeutics LLC 2019-01-24 US disclosed
CN-108218808-A A kind of preparation method of Ritonavir 盐城迪赛诺制药有限公司 2018-06-29 CN disclosed
US-7414067-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2008-08-19 US disclosed
CN-1247554-C Process for synthesizing ritonavir UNIV XIAMEN (CN) 2006-03-29 CN disclosed
CN-1554647-A Process for synthesizing ritonavir 厦门大学 2004-12-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10588894-B2 Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease HRAS, KRAS, NRAS SCN1A 3170/4885SCN2A 3806/4885SCN3A 3444/4885
US-20190022074-A1 COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE HRAS, KRAS, NRAS SCN1A 3170/4885SCN2A 3806/4885SCN3A 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.